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In-vitro activity of temafloxacin for Gram-positive pathogens
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The antimicrobial activity of temafloxacin against aerobic Gram-positive cocci was
compared to that of ciprofloxacin, ofloxacin, fleroxacin and pefloxacin using the
broth microdilution technique. Temafloxacin was more active than the other four
fluoroquinolones, particularly for viridans streptococci and Streptococcus pneumo-
niae. The MIC^ of temafloxacin was at least four-fold lower than that of cipro-
floxacin and ofloxacin for viridans streptococci and penicillin-susceptible
pneumococci. The MIC^s and MIC^s of temafloxacin were equal to or lower than
those of the other fluoroquinolones for methicillin-susceptible Staphylococcus aureus
(MSSA), methicillin-resistant S. aureus (MRSA), and methicillin-susceptible and
methicillin-resistant coagulase-negative staphylococci. Temafloxacin was more
active against all the other Gram-positive aerobes (except Enterococcus faecalis)
tested than the other fluoroquinolones.
Introduction
Streptococcus pneumonias and other Gram-positive cocci remain important human
pathogens. While penicillin has been active against these organisms for many years, its
wide and often indiscriminate use has led to penicillin resistance, with estimated
prevalence rates of between 10% and 40% in parts of Europe (Baquero,
Martinez-Beltran & Loza, 1991). Thus, the search for new therapeutic agents with
activity against penicillin-resistant Gram-positive cocci is important. One such group of
antimicrobial agents is the fluoroquinolones.
The antimicrobial activity of temafloxacin is distinguished from that of other
fluoroquinolones by its extended activity against Gram-positive aerobes (particularly
Gram-positive cocci), intracellular organisms (Chlamydia, Mycoplasma, and Legionella
spp.) and anaerobes. This increased activity is especially relevant to S. pneumoniae. The
MICJO and MIC^ of temafloxacin for S. pneumoniae were reported to be 0-25 mg/L and
<0-5mg/L, respectively (Loza et al., 1990; Digranes et al., 1989). The MIQoS of
ofloxacin and ciprofloxacin for the same isolates were approximately two-fold greater.
In the present study the in-vitro activity of temafloxacin was determined for a range
of recent Gram-positive clinical isolates and compared with that of four other
fluoroquinolones.
Materials and methods
A total of 190 Gram-positive pathogens recently isolated from patients at the
University Hospital, Lausanne, were initially frozen at -80°C in lysed horse blood.
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Table. In-vitro activity of temafloxadn, ciprofloxacin, ofloxadn, fleroxacin and pefloxacin for
Gram-positive aerobic clinical isolates
Organ ism/quinolone
Mcthicillin-susceptible S. aweus (25)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
Methidllin-resistant S. aureus (25)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
Methidllin-susceptible
coagulase-negative
staphylococd (25)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
Methidllin-resistant
coagulase-negative
staphylococd (25)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
Group A /J-haemolytic
streptococd (12)
temafloxadn
dprofloxadn
ofloxadn
fleroxacin
pefloxacin
Group B /?-haemolytic streptococd (11)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
S. viridans (25)
temafloxadn
dprofloxadn
ofloxadn
fleroxadn
pefloxadn
range
0-12-0-5
0-25-1
0-25-1
0-5-1
0-25-1
0-06-4
0-12-32
0-25-16
0-25-32
0-25-64
0-12-4
0-12-4
0-25-8
0-5-16
0-5-16
0-12-2
0-25-2
0-25-2
0-5-8
0-25-8
006-0-5
0-25-0-5
0-5-1
0-5-8
2-16
0O6-1
0-12-1
0-25-2
2-8
2-8
0.008-1
0-12-8
0-12-4
0-12-16
006-16
MIC (mg/L)
MICJO
0-25
0-5
0-5
0-5
as
0-12
0-25
0-25
0-5
0-25
0-25
0-5
0-5
1
0-5
0-25
0-5
0-5
1
0-5
0-25
0-5
1
4
4
0-5
0-5
1
4
4
006
1
2
4
4
MIC*
0-25
0-5
0-5
1
0-5
0-25
0-5
0-5
1
0-5
1
2
2
8
8
0-5
0-5
1
1
1
0-5
0-5
1
8
8
1
1
2
8
8
0-12
4
4
8
8
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Organism/quinolone range
MIC (mg/L)
MICM
Enterococcus faecalis (17)
temafloxadn
ciprofloxacin
ofloxacin
fleroxacin
Penicillin-susceptible S. pneumoniae (17)
temafloxadn
ciprofloxacin
ofloxacin
fleroxacin
pefloxarin
Penicillin-resistanf S. pneumoniae (8)
temafloxadn
ciprofloxacin
ofloxacin
fleroxadn
pefloxadn
0-5-^
0-25-4
1-4
2-8
< 0004-012
0-25-4
0-5-2
2-4
1-16
<0O04-0-12
0-12-2
1-2
2-4
2-4
1
1
4
8
0-12
0-5
1
4
2
006
0-5
1
4
4
4
2
4
8
0-12
4
2
4
16
0-12
2
2
8
4
•Penicillin MIC: range 0-12-20; MIC* 10; MIC,, 20.
Susceptibility of the isolates to temafloxadn, ciprofloxacin, ofloxacin, fleroxacin, and
pefloxadn was determined by the broth microdilution technique in accordance with
NCCLS recommendations (NCCLS, 1982). The medium was a unique batch of
Mueller-Hinton broth with cation supplementation (50 mg/L Ca++, 25 mg/L Mg++).
The inoculum was lO^cfu/mL (lf/cfu/well of microtitre plate).
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Figure 1. Distribution of MIC values for methidllin-tusceptible S. aureus. • • Temafloxadn; • , ciproflox-
acin; O, ofloxacin.
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Figure 2. Distribution of MIC values for methicillin-resutant S. aureus. Q, Tcrnafloxadn; • , ciproflox-
acin; O. ofloxacin.
Results
Temafloxacin was more active against Gram-positive bacteria than were ciprofloxacin
and the three other fluoroquinolones (Table). Temafloxacin was particularly active for
viridans streptococci and S. pneumoniae. The MIC*, of temafloxacin for viridans
streptococci was 012 mg/L, compared to 4 mg/L of ciprofloxacin and ofloxacin. The
100
in
h
ib
it
ed C
D o
| 60
X 40
u
20
0
-
-
-
-
-
I I i
/
/
J
1 1 1 1 1
<0O04 0004 OOO8 OOI 0-03 0O6 0-12 0 25 0-5
MIC (ma/L)
Figure 3. Distribution of MIC values for methicillin-sutceptible coagulase-negative staphylococci.
D , Temafloxacin; • , dprofloxacin; O. ofloxacin.
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Figure 4. Distribution of MIC values for luethiciUin-resistant coagulase-negative staphylococri.
D. Temafloxacin; • , ciprofloxarin; O. ofloxacin.
MIQo of temafloxacin for penicillin-susceptible pneumococci was 0-12 mg/L, compared
to 4 mg/L of dprofloxacin and 2 mg/L of ofloxacin. A temafloxacin concentration of
012 mg/L inhibited 90% of penicillin-resistant pneumococci, compared to 2 mg/L of
dprofloxacin and ofloxacin.
The distribution of MICs of temafloxarin, dprofloxadn and ofloxacin for staphylo-
cocd are shown in Figures 1 to 4. The MIC^s and MICJOS of temafloxacin were less
than or equal to those of dprofloxadn and ofloxadn for methidllin-susceptible
S. aureus (MSSA), methidllin-resistant S. aurais (MRSA), methidllin-susceptible
coagulase-negative staphylococd, and methidllin-resistant coagulase-negative
staphylococd.
Discussion
Temafloxadn has similar activity to other fluoroquinolones against Gram-negative
aerobic organisms, but its activity is distinguished from that of other fluoroquinolones
by its enhanced potency against Gram-positive aerobes. The activity of temafloxadn
against Gram-positive coed, particularly S. pneumoniae and 5. aureus, exceeds that of
other quinolones (Digranes et al., 1989; Nye et al., 1989; Mazzulli et al., 1990).
Temafloxadn has been shown to possess better in-vitro bacteristatic and bacteriddal
activity against clinically significant staphylccoccal isolates than dprofloxadn and
ofloxadn (Fuchs & Barry, 1991). The improved activity of temafloxadn compared to
earlier fluoroquinolones against Gram-positive bacteria described by other workers has
been confirmed in this institution, with the activity of temafloxadn against staphylo-
cocd at least one tube-dilution lower than the other quinolones tested, and against
S. pneumoniae at least four-fold more active regardless of penicillin susceptibility.
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